Simple benchmark for complex dose finding studies

DOI10.1111/BIOM.12158zbMath1419.62325OpenAlexW2168881814WikidataQ40819161 ScholiaQ40819161MaRDI QIDQ5170208

Ying-Kuen Cheung

Publication date: 22 July 2014

Published in: Biometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1111/biom.12158

zbMATH Keywords

efficacycombination therapyphase I trialsutility scoresmultiple toxicitiesphase I/II trialstoxicity tradeoff

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Related Items (6)

Patient-specific dose finding in seamless phase I/II clinical trials ⋮ A new design of the continual reassessment method ⋮ A continual reassessment method without undue risk of toxicity ⋮ Combined criteria for dose optimisation in early phase clinical trials ⋮ Seamless phase I/II design for novel anticancer agents with competing disease progression ⋮ Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Stochastic approximation and modern model-based designs for dose-finding clinical trials
• Adaptive designs for dose-finding based on efficacy-toxicity response
• Dose-Finding Designs for HIV Studies
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Coherence principles in dose-finding studies
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
• A Random Walk Rule for Phase I Clinical Trials
• Statistical Methods for Rates and Proportions
• A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
• The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
• Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
• Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
• Non-parametric optimal design in dose finding studies

This page was built for publication: Simple benchmark for complex dose finding studies